NEW YORK (GenomeWeb News) – Asuragen has won $3.8 million in new stimulus funding from the National Institutes of Health, which it will use to advance its molecular diagnostics programs for cancer and genetic diseases, the company said today.

The company said that it received the funding through the Small Business Innovation Research and Small Business Technology Transfer programs, and the American Recovery and Reinvestment Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.